Data From Follow-Up Study of KALYDECO™ (ivacaftor) Showed Durable Improvements in Lung Function and Other Measures of Disease in People with Cystic Fibrosis Who Have a Specific Genetic Mutation (G551D)
13:14 EDT 7 Jun 2012 | Businesswire
This article has expired, however you can still
download the PDF.
Preview:
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today new
data from a long-term follow-up study that showed that the improvements
in lung function (forced expiratory volume in one second, FEV1),
respiratory symptoms...
Other Sources for this Article
Vertex Pharmaceuticals Incorporated
Media:
617-444-6992 or mediainfo@vrtx.com
Zach
Barber
Megan Goulart
Dawn Kalmar
or
Investors:
Michael
Partridge, 617-444-6108
More From BioPortfolio on "Data From Follow-Up Study of KALYDECO™ (ivacaftor) Showed Durable Improvements in Lung Function and Other Measures of Disease in People with Cystic Fibrosis Who Have a Specific Genetic Mutation (G551D)"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
